News Article

Contributed by William Truitt, PhD, Department of Cell Biology, Neurobiology, and Anatomy, Neuroscience Graduate Program, University of Cincinnati, College of Medicine, Post Office Box 670521, Cincinnati, OH 45267-0521, USA. Previously we demonstrated the existence of a spinothalamic pathway in the male rat where neural activation is specifically induced by ejaculation.1 This pathway includes the parvocellular […]

Contributed by Jean-Christophe Cassel, PhD, Laboratoire de Neurosciences Cognitives et Comportementales, UMR 7521 Université Louis Pasteur/CNRS, Strasbourg, France & Institut für Experimentelle und Klinische Pharmakologie und Toxikologie der Universität Freiburg, Neuropharmakologisches Labor, Freiburg, Germany. Dr. Cassel and colleagues are the authors of four publications released this quarter using 192-Saporin (Cat. #IT-01) Trying to understand how

Contributed by David J Flavell, PhD, The Simon Flavell Leukaemia Research Unit, Division of Cancer Sciences, University of Southampton Medical School, United Kingdom. I have asked Dr. Flavell to contribute an article on the clinical use of his saporin immunotoxins. Dr. Flavell’s research unit is named after his son, who died from leukemia. At that

Carlos Blanco-Centurion contributes this report resulting from work done for an abstract at the 2001 Society for Neuroscience meeting: Hypocretin B-Saporin Lesions of the Brainstem Increase REM Sleep at Night CA Blanco- Centurion, RJ Salin-Pascual, D Gerashchenko, MA Greco, PJ Shiromani. Harvard Medical School & UNAM, Mexico City. This abstract won the ATS Abstract Award.

Dr. Douglas Lappi, Chief Scientific Officer, Advanced Targeting Systems The field of targeted toxins has made enormous strides in the years since Advanced Targeting Systems introduced the first research targeted toxin in 1994. We now offer 16 different targeted toxins, with more on the way. The number of important papers in high impact journals continues

In September, Advanced Targeting Systems received two Small Business Innovation Research (SBIR) awards from the National Institutes of Health. The first is a Phase II grant from the National Institute of Neurological Disorders and Stroke. This project continues a collaboration with Drs. Joanne Berger-Sweeney (Wellesley College) and Mark Baxter (Harvard University) to further develop the

Dr. Robert Sloviter, University of Arizona, contributes this issue’s article from the laboratories of ATS customers. Dr. Sloviter summarizes his research with SSP-saporin, which he and his graduate student Jennifer Martin used to examine the role of inhibitory neurons in maintaining normal network excitability. The mammalian hippocampus is perhaps the most intensely studied brain region

Advanced Targeting Systems announces the release of its new, very exciting targeted toxin, dermorphin-SAP. It is a conjugate of the mu opioid receptor (MOR) agonist dermorphin and the ribosome-inactivating protein, saporin. Its cytotoxicity to cells that express the MOR promise to make it an important tool in the discovery and definition of the role of

Contributed by Dr. Ann Schreihofer, University of Virginia, contributes this issue’s article from the laboratories of ATS customers. Dr. Schreihofer summarizes her research with anti-DBH-SAP (Cat. #IT-03) to immunolesion specific rostral ventral medulla neurons that project to the spinal cord by injection of anti-DBH-SAP into the rat spinal cord. The toxin is taken up and